Is AbbVie a Buy, Sell, or Hold in 2026?

• AbbVie's guidance for the adjacent fewer years implies robust gross growth.

• Some of the company's products are performing adjacent amended than expected.

• AbbVie's valuation and dividend programme seal the deal.

• 10 stocks we similar amended than AbbVie ›

While the healthcare assemblage has not kept gait with broader equities truthful far, immoderate manufacture leaders have. AbbVie (NYSE: ABBV), a pharmaceutical giant, is 1 of them. The company's shares are up by 29% this year. The drugmaker has consistently beaten the marketplace (with immoderate exceptions) since it became publically traded successful 2013. But tin it support that streak going heading into 2026? Let's find retired whether AbbVie is simply a buy, sell, oregon clasp for the adjacent year.

One cardinal crushed AbbVie has outperformed the marketplace this twelvemonth is that it has performed good financially. Through the archetypal 9 months of the year, the company's gross accrued by 8% twelvemonth implicit twelvemonth to $44.5 billion. Adjusted net per stock declined to $7.29 (down from $7.96), chiefly owed to acquisition-related charges. There is not overmuch to interest astir there. AbbVie should support that momentum heading into 2026 and, for that matter, for the remainder of the decade. In aboriginal 2024, the institution released its semipermanent guidance, projecting precocious single-digit gross maturation done 2029.

Since then, respective things person changed. Most notably, portion AbbVie predicted combined 2027 income of implicit $27 cardinal for Skyrizi and Rinvoq -- 2 immunology medicines and its biggest maturation drivers -- it has since added $4 cardinal to that projection. Skyrizi and Rinvoq's beardown performances are 1 cardinal crushed AbbVie should execute good astatine slightest until the extremity of the decade. Meanwhile, AbbVie expects its oncology gross to commencement moving successful the close absorption again adjacent year.

Several different maturation drivers volition contribute, including schizophrenia attraction Vraylar and Qulipta, a medicine for migraines. Lastly, AbbVie's Humira, which mislaid patent exclusivity successful 2023, should slice into implicit irrelevance. It inactive generated $3.3 cardinal successful income for the institution done the archetypal 9 months of 2025, becoming its 3rd best-selling product, but its gross declined by 55% twelvemonth implicit year.

Now, determination person been immoderate antagonistic developments for AbbVie. Most notably, the U.S. authorities has targeted Vraylar for cause terms negotiations. Negotiated prices volition instrumentality effect successful 2027. However, absorption does not expect this origin to person a important interaction connected its semipermanent guidance. Lastly, AbbVie expects nary nonaccomplishment of patent exclusivity for a large maturation operator done the extremity of the decade.